SUZHOU, China, Sept. 8, 2021 /PRNewswire/ — Kintor Pharmaceutical Restricted (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology firm growing progressive small molecule and organic therapeutics, right this moment introduced the first endpoint of part II medical trial of pyrilutamide (“KX-826”, tincture) in China for the therapy of androgenetic alopecia (AGA) was met, which was statistically important and clinically significant.
The part II medical trial was a multicenter, randomized, double-blinded, placebo-controlled examine to evaluate the efficacy and security of KX-826 for the therapy of male AGA adults (N=120). The first endpoint for the trial was the change from baseline in non-vellus goal space hair counts (TAHC) at week 24 as compared with placebo.
Nearly all of antagonistic occasions (AEs) have been delicate and no severe antagonistic occasion (SAE) was reported. KX-826 was well-tolerated and no new security alerts have been noticed. Detailed knowledge might be launched later upon the finalization of the medical examine report. 5mg (0.5%) KX-826 was decided because the dose to be taken into part III medical trial in China, which we count on to kick off the work in This autumn 2021.
Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, “We’re delighted to see the first endpoint in KX-826’s part II examine for AGA was met. A whole bunch of hundreds of thousands of individuals all over the world are troubled with AGA, accounting for roughly 90% of sufferers with hair loss. There may be an pressing want for a safer and more practical drug to handle this downside. We’re conducting part II medical trial of KX-826 for the therapy of male AGA sufferers within the US and can speed up the progress of part III medical trial of KX-826 for the therapy of male AGA sufferers in China. We additionally goal to conduct part II medical trial for feminine AGA sufferers in China, in order to deliver advantages to the folks affected by AGA across the globe as quickly as attainable.”
About Kintor Pharmaceutical Restricted
Kintor Pharmaceutical Restricted is growing and commercializing a strong pipeline of small molecule and organic medicine for androgen-receptor-related illness areas with unmet medical wants, together with COVID-19, prostate, breast and liver most cancers, alopecia and pimples. For extra info, go to www.kintor.com.cn.
SOURCE Kintor Prescription drugs